Coronary artery disease (CAD) is one of the most significant public health problems in western countries. In Finland, on average 150 people die because of CAD every week. CAD narrows coronary arteries that reduces the blood flow in myocardium and may lead to myocardial infarction and heart failure. Current therapies of CAD are mainly focused on plasma lipid lowering, but more effective therapies are needed. Long non-coding RNAs (lncRNAs) that are not translated into proteins, are a large unknown group of molecules, but have been recognized in several disease pathologies and are the hot topic in the development of new therapies. The present study aims to investigate the mechanisms of circular lncRNAs, found from the genetic risk region of CAD, for the treatment of CAD by utilizing latest methods of molecular biology and the technologies of ATMP-products (advanced therapy medicinal products).

2022

2025